$Heart failure with preserved ejection fraction in coronavirus disease 2019 patients: the promising role of diuretic therapy in critically ill patients$

Heart failure with preserved ejection fraction in coronavirus disease 2019 patients: the promising role of diuretic therapy in critically ill patients

The impact of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) on diastolic function is less known. We describe a 46‐year‐old man with a history of mild hypertension who presented to the emergency department with fever, cough, and myalgia for 2 days. The patient was tested positive for S...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	ESC Heart Failure 2021-04, Vol.8 (2), p.1610-1614
Hauptverfasser:	Chitsazan, Mitra, Amin, Ahmad, Chitsazan, Mandana, Ziaie, Naghmeh, Amri Maleh, Parviz, Pouraliakbar, Hamidreza, Von Haehling, Stephan
Format:	Artikel
Sprache:	eng
Schlagworte:	Asymptomatic Blood pressure Blood tests Cardiac & Cardiovascular Systems Cardiovascular disease Cardiovascular System & Cardiology Case Report Case Reports Coronaviruses COVID-19 COVID-19 - complications COVID-19 - diagnosis COVID-19 - therapy Cytokines Diabetes Diastolic heart failure Diuretic Diuretics - therapeutic use Edema Ejection fraction Fatalities Fever Furosemide - therapeutic use Heart failure Heart Failure - diagnosis Heart Failure - therapy Heart Failure - virology Heart failure with preserved ejection fraction (HFpEF) Hemoglobin Humans Hypertension Hypoxia Infections Life Sciences & Biomedicine Male Middle Aged Myocarditis N‐Terminal Pro‐B‐Type Natriuretic Peptide (NT‐proBNP) Older people Oxygen saturation Pandemic Patients Pneumonia Respiration SARS‐CoV‐2 Science & Technology Severe acute respiratory syndrome coronavirus 2 Stroke Volume Ventilators
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!